We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pharmacovigilance practice among pediatric neurologists from Poland and Germany.
- Authors
Kopciuch, Dorota; Kus, Krzysztof; Niśkiewicz, Izabela; Fliciński, Jędrzej; Zaprutko, Tomasz; Ratajczak, Piotr; Nowakowska, Elżbieta; Hoffmann, Karolina; Koligat-Seitz, Agnieszka; Bryl, Wiesław; Paczkowska, Anna
- Abstract
Objectives: To compare the pediatric neurologists' knowledge, practice, and barriers to the pharmacovigilance (PV) process in Poland and Germany. Methods: The research tool was an online anonymous questionnaire on Google Forms e-mailed to pediatric neurologists from Poland and Germany. Results: The questionnaires were handed out to 830 pediatric neurologists and 371 expressed their consent to participate in the study. Most of the neurologists were familiar with the definition of PV and adverse drug reactions (ADRs). Only 34.10% of pediatric neurologists from Poland, and 38.88% from Germany believe that many ADRs are preventable and almost most of them believe it is necessary to report ADRs from children with epilepsy. Unfortunately, in opposite to this knowledge, only 37.79% of respondents from Poland and 40.32% from Germany felt co-responsible for reporting ADRs. The main reason for the neurologists not to report ADRs was a conviction that reporting ADRs would be an additional burden generating extra work. Conclusion: There is no big difference between the practice of PV by pediatric neurologists in Poland and Germany. System-regulated PV stabilization in the country translates into the practice of maintaining PV. Monitoring the safety of pharmacotherapy and knowledge of risks associated with ADRs should be included in the curricula of academic neurologics courses. Key points: In the case of children with epilepsy, neurologists are those instances who are first informed about alarming symptoms by their patients, therefore full participation and engagement of neurologists in the pharmacovigilance (PV) process in epileptic children are crucial to ensure their safe pharmacotherapy. Most of the neurologists were familiar with the definition of PV and adverse drug reactions (ADRs) and believe it is necessary to report ADRs from children with epilepsy. Only 37.79% of pediatric neurologists from Poland and 40.32% from Germany felt co-responsible for reporting ADRs. The main reason for the neurologists not to report ADRs was a conviction that reporting ADRs would be an additional burden generating extra work. Plain Language Summary: Epilepsy is a chronic disorder characterized by episodic, gratuitous seizures. Most children with epilepsy (CWE) rely on antiepileptic drugs causing adverse drug reactions (ADRs). Many ADRs are preventable if physicians actively participate in pharmacovigilance (PV), which its pivotal role is to ensure the safety of pharmacotherapy by e.g. permanent control of ADRs. The study aimed to compare the pediatric neurologists' (PN) knowledge, practice, and barriers to the PV process in Poland and Germany. The research tool was an online anonymous questionnaire on Google Forms e-mailed to PN from Poland and Germany. Only 34.10% of PN from Poland and 38.88% from Germany believe that many ADRs are preventable and almost most of them believe it is necessary to report ADRs from CWE. Unfortunately, in opposite to this knowledge, only 37.79% of respondents from Poland and 40.32% from Germany felt co-responsible for reporting ADRs. The main reason for the neurologists not to report ADRs was a conviction that reporting ADRs would be an additional burden generating extra work. There is no big difference between the practice of PV by PN in Poland and Germany. System-regulated PV stabilization in the country translates into the practice of maintaining PV.
- Subjects
POLAND; GERMANY; EPILEPSY; NEUROLOGISTS; CHILDREN with epilepsy; DRUG side effects; CHILDHOOD epilepsy; MEDICATION safety
- Publication
BMC Medical Education, 2023, Vol 23, Issue 1, p1
- ISSN
1472-6920
- Publication type
Article
- DOI
10.1186/s12909-023-04542-4